Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 3-day suspension order for the drug license of a single store located at Appaswamy Salai Ponga Nagar in Tamil Nadu. The order was issued by the Assistant Director, Drugs Control Administration, Thiruvallur Zone, and was received on June 27, 2025. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the associated rules. The company has quantified the potential revenue loss at approximately Rs 0.38 lakhs due to this suspension. This is a routine regulatory disclosure under SEBI LODR Regulation 30.
The financial impact is negligible — a 3-day license suspension at one store leads to an estimated loss of just Rs 0.38 lakhs. No material effect on overall operations or stock price is expected, though repeated such actions could draw regulatory attention.